TG Therapeutics
TGTX
52.95
+0.76
+1.46%
TG Therapeutics
US · TGTX
#1638 by market cap
Listed 1970
52.95
+0.76
+1.46%
Live - 5344 symbols - heartbeat 260s ago
· 2026-10-08 07:00
Pre-market
52.91
-0.08%
After-hours
53.18
+0.43%
- Market cap
- 8.11B
- P/E (TTM)i
- 19.32
- P/Bi
- 13.42
- EPSi
- 2.77
- Div yieldi
- 0.00%
- 52W posi
- 80%
Reader sentiment
Are you bullish or bearish on TGTX?
Anonymous reader poll. Unscientific, not investment advice.
About TG Therapeutics
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
- Founded
- 1993
- CEO
- Mr. Michael S. Weiss
- Employees
- 399
- Headquarters
- Morrisville, North Carolina, United States of America
- Fiscal year end
- 12-31
- Website
- tgtherapeutics.com
Company profile
- Exchange
- US
- Symbol
- TGTX
- Market-cap rank
- #1638
- Listing date
- 1970-01-01
- Market cap
- 8.11B
- Float cap
- 7.76B
- Shares out
- 153.07M
- Float shares
- 146.46M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 07:00:04 · For reference only, not investment advice and not tailored to your situation.